Tirzepatide, the next step in GLP-1 therapy.

On weight loss alone, head-to-head trials favor tirzepatide at the higher doses. It’s not automatically the right choice for everyone, though. Cost, side-effect profile, and how your body handles dual-receptor therapy all matter. We’ll walk through the trade-offs at your visit.

Mounjaro and Zepbound are FDA-approved brand products. Compounded tirzepatide is not FDA-approved and has not been established as equivalent to either. Matching a stated ingredient or dose does not establish matching safety, quality, or clinical results. Ask your prescriber to explain your exact product and its risks. Read FDA guidance.

GI side effects lead the list: nausea, reflux, constipation, occasional diarrhea. They’re almost always dose-related and improve with slower titration. Less commonly: gallbladder issues, pancreatitis, and thyroid concerns, which is why we run labs and follow up regularly.

Appetite typically drops in the first two weeks. Visible weight loss usually starts around week four and accelerates as the dose climbs. Expect the biggest changes between month three and month nine.

Yes, and it’s a common path. We review your current labs and dose, then start tirzepatide at a titration that fits where you are. Most patients cross over without a washout period.

Compounded GLP-1/GIP medications are self-pay, and brand coverage for weight loss remains inconsistent. Eli Lilly now sells Zepbound vials direct to cash patients, which changed the math for a lot of people, so we walk through both routes with real numbers at your visit rather than assuming ours wins. HSA and FSA funds are usually eligible either way.

Like any rapid weight loss, a portion of the loss can be lean mass, and tirzepatide moves weight fast. We counter it with a protein target set against your goal weight (0.8 to 1.0 g per pound), resistance training two to three times per week, and an InBody scan at every monthly visit. That scan is the point: it separates fat mass from skeletal muscle, so we catch muscle loss in the month it starts rather than at the end.

Moderate alcohol is fine for most patients. Delayed gastric emptying can intensify the effect of alcohol, so expect to feel it faster and longer. We recommend dialing back initially and seeing how you respond.

Without a taper and a maintenance plan, most patients regain significant weight within six to twelve months. We build the exit plan at the start: a slow taper, a maintenance dose for many, and intentional lifestyle anchors.

Oliver Morris, DO is the prescribing physician at Olympia Aesthetics & Wellness. You see him at every visit. Learn more on the Oliver Morris, DO bio page.

Fair question, and the price drop is real. What a manufacturer or a website sells you is the drug. What we sell is the drug plus the medicine around it: a physical exam, labs that get repeated, a monthly body composition scan so we can prove you are losing fat rather than muscle, dose decisions made on your data, and a physician who picks up the phone when something goes wrong. If you would rather have the vial and manage the rest yourself, that is a reasonable choice and we will say so. We just will not pretend the two are the same thing.

Yes. We are not locked into compounded medication. If the brand product is the better fit for your dose, your coverage, or your tolerance, we will write it and manage you on it. The exam, labs, scans, and follow-up are identical either way.

InBody is a body composition analyzer. You stand on it for about a minute and it separates your weight into fat mass, skeletal muscle mass, and body water. It matters more on tirzepatide than on almost anything else, because the weight comes off fast and a meaningful share of it can be muscle if nobody is measuring. The monthly scan is what tells us whether to advance your dose, hold it, or fix your protein and training first.

Yes, and on a dual-agonist it matters more, not less. Tirzepatide titrates across a wide dose range and moves weight quickly, so the monthly exam, scan, and lab checkpoints are what keep the pace safe. Patients who skip in-person follow-up are the ones who plateau on the wrong dose, lose lean mass without knowing it, or sit on a side effect that should have been managed weeks earlier. Visits run about 20 minutes.